Physician profile
James Rawson
NPI 1659380673
$320.27
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $237 · 2020: $32.11 · 2021: $12.94 · 2022: $14.42 · 2024: $24.27.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $24.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $24.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $123.00 | 2019 | |
| Abbvie INC. | $48.01 | 2019-2021 | |
| Janssen Biotech, INC. | $29.74 | 2019 | |
| Mauna Kea Technologies, INC. | $24.27 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.10 | 2019 | |
| Gilead Sciences, INC. | $22.42 | 2019 | |
| Celgene Corporation | $14.42 | 2022 | |
| Merck Sharp & Dohme LLC | $12.21 | 2019 | |
| Braintree Laboratories, INC. | $11.74 | 2020 | |
| Pfizer INC. | $11.36 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Rawson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.